Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Oral solution NRT?

This article was originally published in The Tan Sheet

Executive Summary

Nicoworldwide is pursuing FDA approval of generic nicotine polacrilex, bitartrate and base solutions equivalent to GlaxoSmithKline's Commit nicotine lozenge. In three separate ANDA suitability petitions submitted to FDA in early July, the Pacific Palisades, Calif.-based firm requests permission to file ANDAs for the three nicotine drugs, all in a 2 mg and 4 mg base per 240 mL oral solution. Although the proposed products would feature a different dosage form than the GSK lozenge, they would "not differ from the listed drug in strength (base form) or route of delivery," Nicoworldwide says...
Advertisement

Related Content

Oral solution NRT

Topics

Advertisement
UsernamePublicRestriction

Register

PS097119

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel